Direct effect of an acyl‐CoA:cholesterol acyltransferase inhibitor, F‐1394, on atherosclerosis in apolipoprotein E and low density lipoprotein receptor double knockout mice
Open Access
- 1 August 2001
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 133 (7) , 1005-1012
- https://doi.org/10.1038/sj.bjp.0704160
Abstract
The acyl‐CoA:cholesterol acyltransferase (ACAT) enzyme is thought to be responsible for foam cell formation and the subsequent progression of atherosclerosis. The apolipoprotein E and low density lipoprotein receptor double knockout (apoE/LDLr‐DKO) mouse is an animal model that develops severe hyperlipidaemia and atherosclerosis. Here we have examined the effect of oral administration of an ACAT inhibitor, F‐1394, on atherosclerosis in apoE/LDLr‐DKO mice fed a regular chow diet. In en face analysis, a dose of 10, 30, or 100 mg kg−1 day−1 F‐1394 for 10 weeks reduced the extent of lesions visible in the aorta by 24, 28 and 38%, respectively, as detected by staining with oil red O, without affecting serum cholesterol level in these mice. At the highest dose 100 mg kg−1 day−1 of F‐1394, the reduction was statistically significant. For quantitative analysis of the cellular and non‐cellular components comprising the lesions at the aortic sinus, the effects of an oral dose of 100 mg kg−1 day−1 F‐1394 for 15 weeks were studied. There was a significant reduction (31.9%) in the oil‐red O‐stained area in cross‐sections of the aortic sinus. In addition, the neointimal area, as well as levels of ACAT‐1 protein tended to be decreased (15.2 and 25.8%, respectively, not significant). However, the areas containing macrophages, smooth muscle cells, and collagen were not affected by F‐1394. In vitro, F‐1394 attenuated foam cell formation in mouse peritoneal macrophages. These results indicate that ACAT may be primarily responsible for lipid accumulation in atherosclerotic lesions, and that its inhibition diminishes the lipid deposition via a direct effect on macrophages in the arterial wall. British Journal of Pharmacology (2001) 133, 1005–1012; doi:10.1038/sj.bjp.0704160Keywords
This publication has 37 references indexed in Scilit:
- Effects of F-1394, an Acyl-CoA:Cholesterol Acyltransferase (ACAT) Inhibitor, on ACAT Activity in HepG2 Cells and on Hepatic Secretion of Lipids in Triton WR-1339-Induced Hyperlipidemic Rats: Possible Role of Hepatic ACAT in Very Low Density Lipoprotein SecretionThe Japanese Journal of Pharmacology, 1998
- Collagen quantitation by video-microdensitometry in rabbit atherosclerosisMatrix Biology, 1996
- Effect of FR145237, a novel ACAT inhibitor, on atherogenesis in cholesterol-fed and WHHL rabbits. Evidence for a direct effect on the arterial wallBiochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1995
- Hypocholesterolemic Action and Prevention of Cholesterol Absorption via the Gut by F-1394, a Potent Acyl-CoA:Cholesterol Acyltransferase (ACAT) Inhibitor, in Cholesterol Diet-Fed RatsThe Japanese Journal of Pharmacology, 1995
- Studies on Acyl-CoA:Cholesterol Acyltransferase (ACAT) Inhibitory Effects and Enzyme Selectivity of F-1394, a Pantotheic Acid DerivativeThe Japanese Journal of Pharmacology, 1995
- Effect of the acyl-CoA:cholesterol acyltransferase inhibitor, E5324, on experimental atherosclerosis in rabbitsAtherosclerosis, 1994
- Spontaneous Hypercholesterolemia and Arterial Lesions in Mice Lacking Apolipoprotein EScience, 1992
- Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cellsPublished by Elsevier ,1992
- Endothelial Expression of a Mononuclear Leukocyte Adhesion Molecule During AtherogenesisScience, 1991
- THE DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUMJournal of Clinical Investigation, 1955